| Labcorp

September 27, 2023

Advance Your Cell and Gene Therapies With Scientific Insights Across Every Stage of Development

Cell and gene therapies (CGT) are bringing new options to patients while revolutionizing the future of medicine. As you drive this innovation, we're here to provide the global infrastructure you need combined with the personalized experience you deserve.

September 27, 2023

Five surprising factors that influence your road to the clinic

When setting out to start a cell or gene therapy program, many biotech and pharmaceutical companies inadvertently assume that the preclinical drug development milestones will be similar to traditional therapies.

September 28, 2023

Cell & gene therapy preclinical testing solutions

We are committed to helping you transform the future of healthcare by bringing promising cell and gene therapies to more patients.

September 28, 2023

End-to-end drug and diagnostic development support for an immuno-oncology agent

Immuno-oncology drug development is inherently complex and requires special considerations across the entire spectrum, from preclinical to commercial support for the approved product.

September 28, 2023

Cell and gene therapy: Overview, current landscape and future trends

This white paper provides an engaging background on cell and gene therapies, a look into recent therapeutic applications and future trends in the cell and gene therapy technology space.

September 28, 2023

Cell therapy for treatment of cancer

This white paper provides the current position on the key cell types and their role in cancer immunotherapies, with a more in-depth focus on chimeric antigen receptor (CAR) T-cell therapies.

October 3, 2023

Nonclinical considerations for cell and gene therapies

With nearly a dozen or more products commercialized globally and approximately 1000 clinical trials underway as of the end of 2018, cell and gene therapies are significant component for drug development.

<span>Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant</span>

October 4, 2023

Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant

CPI RNA Vaccines 2023 -- A vaccine against Marburg virus is being developed using a self-amplifying messenger RNA (sa mRNA) for the Marburg Glycoprotein (MARV GP) antigen. The vaccine comprises the sa mRNA encapsulated into a lipid nanoparticle (LNP) for protection of the RNA and cellular delivery.

October 4, 2023

Rational selection of Toll-like receptor agonists (TLR) for the development of Marburg vaccine formulation

CPI RNA Vaccines 2023 -- Marburg virus infection causes haemorrhagic fever with fatality rates of up to 88%. Provision of a vaccine to Marburg virus is an unmet medical need.

October 4, 2023

A basic overview of hemocompatibility

Hemocompatibility refers to the ability of a device to cause hemolysis (rupture of red blood cells), clotting, formation of a thrombus or activation of the complement system. Hemocompatibility testing is essential for evaluating the interactions of medical devices having contact with blood.

Kümmern Sie sich um Ihre Gesundheit

Krankheiten und Therapiebereiche

Behandlungsmodalitäten und -methoden

Wissenschaftliche Labordisziplinen

Labore

Branchen

Advance Your Cell and Gene Therapies With Scientific Insights Across Every Stage of Development

Five surprising factors that influence your road to the clinic

Cell & gene therapy preclinical testing solutions

End-to-end drug and diagnostic development support for an immuno-oncology agent

Cell and gene therapy: Overview, current landscape and future trends

Cell therapy for treatment of cancer

Nonclinical considerations for cell and gene therapies

Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant

Rational selection of Toll-like receptor agonists (TLR) for the development of Marburg vaccine formulation

A basic overview of hemocompatibility